Tang Capital Management LLC Aligos Therapeutics, Inc. Transaction History

Tang Capital Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$0.64 - $1.13 $345,502 - $610,027	-539,847 Reduced 24.65%	1,650,000 $1.62 Million
Q4 2023 Feb 14, 2024	SELL	$0.56 - $0.8 $637,952 - $911,360	-1,139,201 Reduced 34.22%	2,189,847 $1.45 Million
Q2 2023 Aug 14, 2023	SELL	$0.89 - $1.36 $85,219 - $130,222	-95,752 Reduced 2.8%	3,329,048 $3.23 Million
Q1 2023 May 15, 2023	BUY	$0.87 - $2.11 $529,315 - $1.28 Million	608,409 Added 21.6%	3,424,800 $2.98 Million
Q4 2022 Feb 14, 2023	BUY	$0.89 - $28.0 $1.13 Million - $35.5 Million	1,268,681 Added 81.97%	2,816,391 $2.68 Million
Q2 2022 Aug 15, 2022	BUY	$1.04 - $2.14 $1.61 Million - $3.31 Million	1,547,710 New	1,547,710 $1.87 Million

253K

Ticker ALGS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,717,000
Market Cap $751M
Description
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...

Get notified when there are updates to the investment portfolio of Tang Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Tang Capital Management LLC with notifications on news.